{"doc_id": "32719045", "type of study": "Therapy", "title": "", "abstract": "Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study.\nTo prospectively investigate in patients with severe COVID-19-associated cytokine storm syndrome (CSS) whether an intensive course of glucocorticoids with or without tocilizumab accelerates clinical improvement, reduces mortality and prevents invasive mechanical ventilation, in comparison with a historic control group of patients who received supportive care only.\nFrom 1 April 2020, patients with COVID-19-associated CSS, defined as rapid respiratory deterioration plus at least two out of three biomarkers with important elevations (C-reactive protein >100\u2009mg/L; ferritin >900\u2009\u00b5g/L; D-dimer >1500\u2009\u00b5g/L), received high-dose intravenous methylprednisolone for 5 consecutive days (250\u2009mg on day 1 followed by 80\u2009mg on days 2-5).\nIf the respiratory condition had not improved sufficiently (in 43%), the interleukin-6 receptor blocker tocilizumab (8\u2009mg/kg body weight, single infusion) was added on or after day 2.\nControl patients with COVID-19-associated CSS (same definition) were retrospectively sampled from the pool of patients (n=350) admitted between 7 March and 31 March, and matched one to one to treated patients on sex and age.\nThe primary outcome was \u22652 stages of improvement on a 7-item WHO-endorsed scale for trials in patients with severe influenza pneumonia, or discharge from the hospital.\nSecondary outcomes were hospital mortality and mechanical ventilation.\nAt baseline all patients with COVID-19 in the treatment group (n=86) and control group (n=86) had symptoms of CSS and faced acute respiratory failure.\nTreated patients had 79% higher likelihood on reaching the primary outcome (HR: 1.8; 95%\u2009CI 1.2 to 2.7) (7 days earlier), 65% less mortality (HR: 0.35; 95%\u2009CI 0.19 to 0.65) and 71% less invasive mechanical ventilation (HR: 0.29; 95%\u2009CI 0.14 to 0.65).\nTreatment effects remained constant in confounding and sensitivity analyses.\nA strategy involving a course of high-dose methylprednisolone, followed by tocilizumab if needed, may accelerate respiratory recovery, lower hospital mortality and reduce the likelihood of invasive mechanical ventilation in COVID-19-associated CSS.\n\u00a9 Author(s) (or their employer(s)) 2020.\nNo commercial re-use. See rights and permissions.\nPublished by BMJ.\n", "Evidence Map": {"Enrollment": [{"term": "COVID-19-associated cytokine storm syndrome", "negation": "affirmed", "UMLS": {}, "start": 127, "end": 170}, {"term": "severe COVID-19-associated cytokine storm syndrome ( CSS )", "negation": "affirmed", "UMLS": {}, "start": 46, "end": 104}, {"term": "COVID-19-associated CSS", "negation": "affirmed", "UMLS": {}, "start": 34, "end": 57}, {"term": "rapid respiratory deterioration plus at least two out of three biomarkers with important elevations", "negation": "affirmed", "UMLS": {}, "start": 71, "end": 170}, {"term": "protein", "negation": "affirmed", "UMLS": {}, "start": 184, "end": 191}, {"term": "COVID-19-associated CSS", "negation": "affirmed", "UMLS": {}, "start": 22, "end": 45}, {"term": "severe influenza pneumonia", "negation": "affirmed", "UMLS": {}, "start": 108, "end": 134}, {"term": "discharge from the", "negation": "affirmed", "UMLS": {}, "start": 140, "end": 158}, {"term": "COVID-19", "negation": "affirmed", "UMLS": {}, "start": 30, "end": 38}], "Comparison Results": [], "Study Arm 1 Results": [], "Study Arm 2 Results": [], "Hypothesis": []}, "Sentence-level breakdown": [{"Section": "TITLE", "Text": "Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome : results of the CHIC study .", "Evidence Elements": {"Participant": [{"term": "COVID-19-associated cytokine storm syndrome", "negation": "affirmed", "UMLS": {}, "start": 127, "end": 170}], "Intervention": [{"term": "glucocorticoids with or without tocilizumab", "negation": "affirmed", "UMLS": {}, "start": 38, "end": 81}, {"term": "supportive care", "negation": "affirmed", "UMLS": {}, "start": 89, "end": 104}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "OBJECTIVES", "Text": "To prospectively investigate in patients with severe COVID-19-associated cytokine storm syndrome ( CSS ) whether an intensive course of glucocorticoids with or without tocilizumab accelerates clinical improvement , reduces mortality and prevents invasive mechanical ventilation , in comparison with a historic control group of patients who received supportive care only .", "Evidence Elements": {"Participant": [{"term": "severe COVID-19-associated cytokine storm syndrome ( CSS )", "negation": "affirmed", "UMLS": {}, "start": 46, "end": 104}], "Intervention": [{"term": "intensive course of glucocorticoids with or without tocilizumab", "negation": "affirmed", "UMLS": {}, "start": 116, "end": 179}, {"term": "historic control", "negation": "affirmed", "UMLS": {}, "start": 301, "end": 317}], "Outcome": [{"term": "clinical improvement", "negation": "affirmed", "UMLS": {}, "start": 192, "end": 212}, {"term": "mortality", "negation": "affirmed", "UMLS": {}, "start": 223, "end": 232}, {"term": "invasive mechanical ventilation", "negation": "affirmed", "UMLS": {}, "start": 246, "end": 277}], "Observation": [{"term": "accelerates", "negation": "affirmed", "UMLS": {}, "start": 180, "end": 191}, {"term": "reduces", "negation": "affirmed", "UMLS": {}, "start": 215, "end": 222}, {"term": "prevents", "negation": "affirmed", "UMLS": {}, "start": 237, "end": 245}], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "From 1 April 2020 , patients with COVID-19-associated CSS , defined as rapid respiratory deterioration plus at least two out of three biomarkers with important elevations ( C-reactive protein > 100 mg / L ; ferritin > 900 \u00b5g / L ; D-dimer > 1500 \u00b5g / L ) , received high-dose intravenous methylprednisolone for 5 consecutive days ( 250 mg on day 1 followed by 80 mg on days 2-5 ) .", "Evidence Elements": {"Participant": [{"term": "COVID-19-associated CSS", "negation": "affirmed", "UMLS": {}, "start": 34, "end": 57}, {"term": "rapid respiratory deterioration plus at least two out of three biomarkers with important elevations", "negation": "affirmed", "UMLS": {}, "start": 71, "end": 170}, {"term": "protein", "negation": "affirmed", "UMLS": {}, "start": 184, "end": 191}], "Intervention": [{"term": "high-dose intravenous methylprednisolone", "negation": "affirmed", "UMLS": {}, "start": 266, "end": 306}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "If the respiratory condition had not improved sufficiently ( in 43 % ) , the interleukin-6 receptor blocker tocilizumab ( 8 mg / kg body weight , single infusion ) was added on or after day 2 .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "interleukin-6 receptor blocker tocilizumab", "negation": "negated", "UMLS": {}, "start": 77, "end": 119}], "Outcome": [{"term": "respiratory condition", "negation": "affirmed", "UMLS": {}, "start": 7, "end": 28}], "Observation": [{"term": "improved sufficiently", "negation": "negated", "UMLS": {}, "start": 37, "end": 58}], "Count": [{"term": "43 %", "negation": "affirmed", "UMLS": {}, "start": 64, "end": 68}]}, "Evidence Propositions": [{"Intervention": "interleukin-6 receptor blocker tocilizumab", "Observation": "improved sufficiently", "Outcome": "respiratory condition", "Count": ""}]}, {"Section": "METHODS", "Text": "Control patients with COVID-19-associated CSS ( same definition ) were retrospectively sampled from the pool of patients ( n = 350 ) admitted between 7 March and 31 March , and matched one to one to treated patients on sex and age .", "Evidence Elements": {"Participant": [{"term": "COVID-19-associated CSS", "negation": "affirmed", "UMLS": {}, "start": 22, "end": 45}], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "The primary outcome was \u22652 stages of improvement on a 7-item WHO-endorsed scale for trials in patients with severe influenza pneumonia , or discharge from the hospital .", "Evidence Elements": {"Participant": [{"term": "severe influenza pneumonia", "negation": "affirmed", "UMLS": {}, "start": 108, "end": 134}, {"term": "discharge from the", "negation": "affirmed", "UMLS": {}, "start": 140, "end": 158}], "Intervention": [], "Outcome": [{"term": "\u22652 stages of improvement on a 7-item WHO-endorsed scale", "negation": "affirmed", "UMLS": {}, "start": 24, "end": 79}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "Secondary outcomes were hospital mortality and mechanical ventilation .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "hospital mortality", "negation": "affirmed", "UMLS": {}, "start": 24, "end": 42}, {"term": "mechanical ventilation", "negation": "affirmed", "UMLS": {}, "start": 47, "end": 69}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "At baseline all patients with COVID-19 in the treatment group ( n = 86 ) and control group ( n = 86 ) had symptoms of CSS and faced acute respiratory failure .", "Evidence Elements": {"Participant": [{"term": "COVID-19", "negation": "affirmed", "UMLS": {}, "start": 30, "end": 38}], "Intervention": [{"term": "treatment", "negation": "affirmed", "UMLS": {}, "start": 46, "end": 55}, {"term": "control", "negation": "affirmed", "UMLS": {}, "start": 77, "end": 84}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "Treated patients had 79 % higher likelihood on reaching the primary outcome ( HR : 1.8 ; 95 % CI 1.2 to 2.7 ) ( 7 days earlier ) , 65 % less mortality ( HR : 0.35 ; 95 % CI 0.19 to 0.65 ) and 71 % less invasive mechanical ventilation ( HR : 0.29 ; 95 % CI 0.14 to 0.65 ) .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "likelihood on reaching the primary outcome", "negation": "affirmed", "UMLS": {}, "start": 33, "end": 75}, {"term": "mortality", "negation": "affirmed", "UMLS": {}, "start": 141, "end": 150}], "Observation": [{"term": "79 % higher", "negation": "affirmed", "UMLS": {}, "start": 21, "end": 32}, {"term": "1.8", "negation": "affirmed", "UMLS": {}, "start": 83, "end": 86}, {"term": "65 % less", "negation": "affirmed", "UMLS": {}, "start": 131, "end": 140}, {"term": "0.35", "negation": "affirmed", "UMLS": {}, "start": 158, "end": 162}], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "Treatment effects remained constant in confounding and sensitivity analyses .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "Treatment effects", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 17}], "Observation": [{"term": "constant", "negation": "affirmed", "UMLS": {}, "start": 27, "end": 35}], "Count": []}, "Evidence Propositions": []}, {"Section": "CONCLUSIONS", "Text": "A strategy involving a course of high-dose methylprednisolone , followed by tocilizumab if needed , may accelerate respiratory recovery , lower hospital mortality and reduce the likelihood of invasive mechanical ventilation in COVID-19-associated CSS .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "high-dose methylprednisolone", "negation": "affirmed", "UMLS": {}, "start": 33, "end": 61}, {"term": "followed by tocilizumab", "negation": "affirmed", "UMLS": {}, "start": 64, "end": 87}], "Outcome": [{"term": "respiratory recovery", "negation": "affirmed", "UMLS": {}, "start": 115, "end": 135}, {"term": "hospital mortality", "negation": "affirmed", "UMLS": {}, "start": 144, "end": 162}, {"term": "likelihood of invasive mechanical ventilation", "negation": "affirmed", "UMLS": {}, "start": 178, "end": 223}], "Observation": [{"term": "accelerate", "negation": "affirmed", "UMLS": {}, "start": 104, "end": 114}, {"term": "lower", "negation": "affirmed", "UMLS": {}, "start": 138, "end": 143}, {"term": "reduce", "negation": "affirmed", "UMLS": {}, "start": 167, "end": 173}], "Count": []}, "Evidence Propositions": [{"Intervention": [], "Observation": "lower", "Outcome": "", "Count": ""}, {"Intervention": "high-dose methylprednisolone", "Observation": "reduce", "Outcome": "likelihood of invasive mechanical ventilation", "Count": ""}, {"Intervention": "followed by tocilizumab", "Observation": "reduce", "Outcome": "likelihood of invasive mechanical ventilation", "Count": ""}]}, {"Section": "UNKNOWN", "Text": "\u00a9 Author (s ) ( or their employer (s ) ) 2020 .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "No commercial re-use . See rights and permissions .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Published by BMJ .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}]}